Moody kids years later: Long-term outcomes of youth from the Omega-3 and therapy (OATS) studies
- PMID: 33285389
- PMCID: PMC7856236
- DOI: 10.1016/j.jad.2020.11.115
Moody kids years later: Long-term outcomes of youth from the Omega-3 and therapy (OATS) studies
Abstract
Background: This naturalistic follow-up study examines outcomes for youth with depression (n = 25) or subsyndromal bipolar disorder (n = 13) 2-5 years after participation in randomized clinical trials (RCTs) of omega-3 fatty acids (Ω3), individual family psychoeducational psychotherapy (IF-PEP), and their combination METHODS: Forty percent (38/95) of RCT families completed a follow-up assessment RESULTS: Relapse rates and conversion to bipolar disorder were consistent with published literature. Original treatment assignment did not impact current functioning. Overall, participants' mood severity, executive functioning, and global functioning continued to be better than at RCT baseline. Depressive symptoms increased significantly from end of RCT. Manic symptom severity, executive functioning, and global functioning remained comparable to end of RCT. The majority of parents and youth reported improved youth emotion regulation skills and family communication. They considered study participation beneficial, with increased understanding of mood disorders being the top reason. Half of youth commenced or continued Ω3 and 58% commenced or continued psychotherapy post-RCT, suggesting some degree of consumer satisfaction; these youth had lower depression severity than other participants.
Limitations: Only 40% returned to this naturalistic follow-up; they were less likely to have an African-American parent, were of higher income, and youth were more symptomatic at end of RCT than those who did not return CONCLUSIONS: Improvement from RCT baseline continued although depressive symptom severity increased from end of RCT to follow-up. Meaningful improvements in youth and family functioning persisted 2-5 years later. Interventions that prevent relapse or conversion to BPSD are still needed for these vulnerable populations.
Copyright © 2020. Published by Elsevier B.V.
Conflict of interest statement
CONFLICTS OF INTEREST
Dr. Fristad receives research funding from Janssen and royalties from American Psychiatry Publishing, Child & Family Psychological Services, Guilford Press, and JK Seminars. Dr. Roley-Roberts has no conflicts to report. Dr. Black receives research support from the American Psychological Foundation and the Smith Richardson Funds. Dr. Arnold has received research funding from Curemark, Forest, Lilly, Neuropharm, Novartis, Noven, Shire, Supernus, Roche, and YoungLiving (as well as NIH and Autism Speaks); has consulted with Gowlings, Neuropharm, Organon, Pfizer, Sigma Tau, Shire, Tris Pharma, and Waypoint; and been on advisory boards for Arbor, Ironshore, Novartis, Noven, Otsuka, Pfizer, Roche, Seaside Therapeutics, Sigma Tau, Shire.
References
-
- American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders (4th ed., Text Revision). Washington, DC: Author.
-
- Asarnow JR, Jaycox LH, Duan N, LaBorde AP, Rea MM, Murray P, … & Wells KB (2005). Effectiveness of a quality improvement intervention for adolescent depression in primary care clinics: A randomized controlled trial. JAMA, 293(3), 311–319. - PubMed
-
- Axelson DA, Birmaher B, Strober MA, Goldstein BI, Ha W, Gill MK, … Keller MB (2011). Course of subthreshold bipolar disorder in youth: Diagnostic progression from bipolar disorder not otherwise specified. Journal of the American Academy of Child and Adolescent Psychiatry, 50(10), 1001–1016.e3. 10.1016/j.jaac.2011.07.005 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
